This study is looking at ways to prevent vision loss from radiation retinopathy, a condition that can affect your vision after treatment for choroidal melanoma (a type of eye cancer). Researchers are comparing two medications, faricimab and fluocinolone acetonide, to simply observing the eye. Faricimab is given as an injection into the eye every three months, and fluocinolone acetonide is a small implant placed in the eye at the start and again after two years. The goal is to see if these treatments can help maintain your vision over three years, specifically by preventing a significant drop in how well you can see. You might be able to join if you are an adult who has received plaque brachytherapy for primary uveal melanoma, have good baseline vision, and your tumor is not too close to the center of your macula (the part of your eye responsible for sharp, central vision). The study is currently unclear on its recruitment status and plans to enroll 600 participants.

Study design

This is a randomized controlled trial, meaning participants will be assigned by chance to receive either faricimab, fluocinolone acetonide, or observation. The study plans to enroll 600 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will measure changes in your vision for up to 3 years after you start the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.